Novo Nordisk will begin a late-stage trial of its experimental next-generation obesity drug CagriSema on Feb. 10 to test its ...

Novo Nordisk will begin a new late-stage trial of its experimental next-generation obesity drug CagriSema on Feb. 10, ...

The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, as well as ...

Ozempic’s expanded approval in the U.S. could transform how doctors treat patients with the condition, which involves a ...

Ozempic belongs to a class of drugs known as GLP-1 receptor agonists and has the same active ingredient as the company's ...

On Friday, however, Novo Nordisk announced top-line results in yet another trial. While the results don't initially sound as ...

Novo Nordisk agreed to cap insulin prices to settle a lawsuit in which Minnesota's attorney general accused the three largest ...

Here are some of the major companies whose stocks moved on the week’s news.

Novo Nordisk shares jumped on Friday as the Danish drugmaker said an experimental drug was able to reduce weight by as much ...

Novo Nordisk shares were 9.5% higher after the pharmaceutical giant said an experimental weight-loss shot showed patients ...

Novo Nordisk A/S rose the most in a month after an experimental shot delivered as much as 22% weight loss in an early-stage ...

The US Food and Drug Administration (FDA) has approved Novo Nordisk’s Ozempic (semaglutide) to reduce certain risks ...